Centessa Pharmaceuticals (CNTA) News Today $16.74 -0.09 (-0.53%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Short Interest in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Increases By 7.0%Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,150,000 shares, a growth of 7.0% from the October 15th total of 2,010,000 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily trading volume, of 604,100 shares, the days-to-cover ratio is presently 3.6 days.November 17, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $28.00 at GuggenheimGuggenheim raised their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday.November 15, 2024 | marketbeat.comB. Riley Has Positive Outlook for CNTA FY2024 EarningsCentessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Research analysts at B. Riley increased their FY2024 earnings per share estimates for Centessa Pharmaceuticals in a research report issued on Tuesday, November 12th. B. Riley analyst M. Mamtani now expects that the company will post earniNovember 15, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 8.4% Following Earnings BeatNovember 15, 2024 | americanbankingnews.comBuy Rating for Centessa Pharmaceuticals: Promising Orexin Program and Strategic Portfolio AdvancesNovember 14, 2024 | markets.businessinsider.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Here's What HappenedCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Time to Sell?November 14, 2024 | marketbeat.comCentessa Pharmaceuticals’ ORX750: Promising Efficacy and Strategic Positioning Reinforce Buy RatingNovember 14, 2024 | markets.businessinsider.comGSA Capital Partners LLP Increases Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)GSA Capital Partners LLP lifted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 66.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 93,658 shares of the company's stock after acquiring an additionaNovember 14, 2024 | marketbeat.comGSA Capital Partners LLP Has $1.50 Million Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)GSA Capital Partners LLP grew its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 66.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 93,658 shares of the company's stock after buying anNovember 14, 2024 | marketbeat.comCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deNxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) AgonistNovember 13, 2024 | finanznachrichten.deCentessa Pharmaceuticals Advances Pipeline with Promising OX2R DataNovember 13, 2024 | markets.businessinsider.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Recommendation of "Buy" by AnalystsNovember 13, 2024 | americanbankingnews.comCentessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year High - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year High - Should You Buy?November 12, 2024 | marketbeat.comCentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateNovember 12, 2024 | globenewswire.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Rating of "Buy" by AnalystsShares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have earned an average rating of "Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month pNovember 8, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Quotes, Forecast and News SummaryNovember 1, 2024 | benzinga.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $180,591.96 in StockOctober 26, 2024 | insidertrades.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 11,742 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 11,742 shares of the business's stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $15.38, for a total value of $180,591.96. Following the transaction, the insider now owns 183,266 shares of the company's stock, valued at $2,818,631.08. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.October 25, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $39,709.44 in StockOctober 24, 2024 | insidertrades.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 2,592 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 2,592 shares of the company's stock in a transaction that occurred on Wednesday, October 23rd. The shares were sold at an average price of $15.32, for a total value of $39,709.44. Following the completion of the sale, the chief executive officer now owns 630,661 shares of the company's stock, valued at $9,661,726.52. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.October 23, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Significant Growth in Short InterestCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,960,000 shares, an increase of 30.7% from the September 15th total of 1,500,000 shares. Approximately 2.5% of the company's shares are sold short. Based on an average daily trading volume, of 589,900 shares, the short-interest ratio is presently 3.3 days.October 15, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Sold by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC cut its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 64.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 26,073 shares of the company's stock after selling 46,536 shares during the perioOctober 15, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Recommendation of "Buy" by BrokeragesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has been given a consensus recommendation of "Buy" by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 mOctober 14, 2024 | marketbeat.comCentessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage BiotechOctober 12, 2024 | msn.comThe Manufacturers Life Insurance Company Acquires 32,846 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)The Manufacturers Life Insurance Company grew its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 30.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 140,894 shares of the company's stockOctober 12, 2024 | marketbeat.comAnalysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising DevelopmentsOctober 10, 2024 | uk.finance.yahoo.comCubist Systematic Strategies LLC Has $235,000 Stock Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Cubist Systematic Strategies LLC lessened its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 64.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,073 shares of the company's stock after selling 46,53October 6, 2024 | marketbeat.comRenaissance Technologies LLC Sells 45,100 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Renaissance Technologies LLC reduced its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 20.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 173,700 shares of the company's stock after selling 45,100 shares duringOctober 5, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 3.3%Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.3%October 2, 2024 | marketbeat.comNantahala Capital Management LLC Buys Shares of 450,000 Centessa Pharmaceuticals plc (NASDAQ:CNTA)Nantahala Capital Management LLC purchased a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 450,000 shares of the companyOctober 1, 2024 | marketbeat.comPoint72 Asset Management L.P. Sells 495,714 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Point72 Asset Management L.P. lowered its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 22.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,762,004 shares of the company's stock after selling 49September 30, 2024 | marketbeat.comDriehaus Capital Management LLC Purchases 987,997 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Driehaus Capital Management LLC boosted its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 89.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,092,011 shares of the company's stock after buying an additional 987,997 shSeptember 29, 2024 | marketbeat.comWake Up to This Biotech Stock That Still Has Big Potential UpsideCentessa Pharmaceuticals released strong results in Phase 1 trials and now Wall Street analysts are buzzing over the stock.September 28, 2024 | marketbeat.comGregory M. Weinhoff Sells 16,619 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockSeptember 28, 2024 | insidertrades.comCentessa Pharmaceuticals’ ORX142 Shows Promising Preclinical Results and Market PotentialSeptember 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)September 27, 2024 | markets.businessinsider.comCentessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)September 26, 2024 | globenewswire.comAffinity Asset Advisors LLC Buys 305,156 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Affinity Asset Advisors LLC increased its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 36.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,135,702 shares of the company's stock after acquiring an additiSeptember 25, 2024 | marketbeat.comFirst Light Asset Management LLC Has $43.17 Million Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)First Light Asset Management LLC raised its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 59.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,780,560 shares of the company's stocSeptember 24, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 6.2% After Insider SellingCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 6.2% Following Insider SellingSeptember 23, 2024 | marketbeat.comBrokers Offer Predictions for Centessa Pharmaceuticals plc's Q3 2024 Earnings (NASDAQ:CNTA)Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Research analysts at B. Riley issued their Q3 2024 earnings estimates for shares of Centessa Pharmaceuticals in a research note issued to investors on Wednesday, September 18th. B. Riley analyst M. Mamtani forecasts that the company willSeptember 23, 2024 | marketbeat.comCentessa shares rise on upgrade to Overweight by Morgan StanleySeptember 21, 2024 | investing.comMorgan Stanley Upgrades Centessa Pharmaceuticals plc - Depositary Receipt () (CNTA)September 21, 2024 | msn.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 SharesSeptember 21, 2024 | insidertrades.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 4.2%Centessa Pharmaceuticals (NASDAQ:CNTA) Trading 4.2% HigherSeptember 20, 2024 | marketbeat.comCentessa Pharmaceuticals rises after upgrade to Overweight at Morgan StanleySeptember 20, 2024 | msn.comCentessa Pharmaceuticals (NASDAQ:CNTA) Upgraded to "Overweight" by Morgan StanleyMorgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $11.00 to $26.00 in a report on Thursday.September 19, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Rating of "Moderate Buy" by AnalystsCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the cSeptember 19, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Research Coverage Started at B. RileyB. Riley initiated coverage on Centessa Pharmaceuticals in a research report on Thursday. They issued a "buy" rating and a $33.00 target price for the company.September 19, 2024 | marketbeat.com Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW CNTA Media Mentions By Week CNTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTA News Sentiment▼0.980.45▲Average Medical News Sentiment CNTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTA Articles This Week▼133▲CNTA Articles Average Week Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACRS News OCGN News VTYX News RPTX News MCRB News AGEN News ASND News LEGN News ELAN News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
